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Research in context 
Evidence before this study 
Several countries or regions within countries have developed effective asthma strategies, 
which, when consistently implemented, resulted in early detection and, subsequently, the 
reduction of the burden and cost of asthma to individuals and society. There has been no 
systematic appraisal of the extent of asthma strategies in the world. 
Added value of this study 
This study surveyed Global Asthma Network investigators in more than half the world’s 
countries and found only about one in four had a national asthma strategy. 
Implications of all the available evidence 
There is potential for a large reduction in the global burden of asthma if more countries 





Abstract (235/250 words) 
Background 
Asthma affects about 334 million people globally, many of whom are unnecessarily disabled. 
Several countries or regions within countries have developed an effective asthma strategy 
resulting in reduction of the burden of asthma to individuals and society. There has been no 
systematic appraisal of the extent of asthma strategies in the world. 
Methods 
The Global Asthma Network (GAN) undertook an email survey of principal investigators of 
GAN centres in 2013-2015. One of the questions was: “Has a national asthma strategy been 
developed in your country for the next five years? For children, for adults?” (Yes/No/Don’t 
Know). The survey was sent to 276 investigators in 120 countries.  
Findings 
213 (77.2%) investigators in 112 (93.3%) countries answered this question. Of these 
countries, 26 (23.2%) reported a national asthma strategy for children and 24 (21.4%) for 
adults; 22 (19.6%) countries had strategies for both children and adults; 28 (25%) had a 
strategy for at least one age group. Strategies were more significantly common in countries 
with high prevalence of current wheeze than low prevalence (11/13 (85%) and 7/31 (22.6%) 
respectively, p<0.001). 
Interpretation 
In about one in four countries a national asthma strategy was reported. As the global 
prevalence of asthma has risen, especially in the most populated countries, a large reduction 
in the global burden of asthma could be achieved potentially, if more countries had effective 
asthma strategies. 
Funding 







Asthma is a common chronic disease affecting about 334 million children and adults in the 
world (1, 2). The Global Burden of Disease Study 2010 found the asthma was the 14th 
highest ranked cause of Years Lived with Disability (3). Many people with asthma are 
unnecessarily disabled, because they are not receiving optimal asthma management (4). In 
2010, it was estimated that about 22 million disability-adjusted life years are lost because of 
asthma (5). The International Study of Asthma and Allergies in Childhood (ISAAC) found 
that the historical view of asthma being a disease of high-income countries (HICs) no 
longer holds: most people affected are in low- and middle-income countries (LMICs), and 
asthma prevalence is estimated to be increasing fastest in those countries (6), where most 
of the world’s people live.  
To reduce the burden of asthma, several HICs and LMICs have developed asthma 
strategies (or asthma programmes which is the terminology used by some countries) at a 
national or regional level which have resulted in rapid reduction of the ill-effects of asthma 
(7). The strategies or programmes are formalised with political engagement and 
commitment. Implementation of such strategies includes relatively simple measures which 
are consistently applied in the relevant population, to improve early detection of asthma and 
provide access to effective anti-inflammatory treatment. Extension of this approach to other 
countries or regions within countries could be of great potential benefit to reducing the 
burden of asthma in the world.  
The first comprehensive national asthma strategy was developed in Finland in 1994 and has 
served as a model for other countries. They developed and called it a comprehensive 
nationwide Asthma Programme and over the next decade this lessened the burden of 
asthma on individuals and society and more than halved the total asthma costs (healthcare, 
drugs, disability, and productivity loss) (8, 9) and these benefits have continued (10). This 
model was followed several years later by several other strategies within the European 
Union (11) including France (12), Portugal (13), and Spain (14). In other places, independent 
approaches have been used with improved outcomes, including Australia (15, 16), the city of 
Salvador, Brazil (17), Canada (18), Costa Rica (19), Singapore (20), Tonga (21) and Turkey 
(22). 
There are few reports of such strategies, suggesting that in many countries there is no 
strategy or it has not been implemented, but there has been no systematic appraisal of the 
extent of asthma strategies in the world. The Global Asthma Network (GAN) was established 
in 2012, a collaboration between individuals from ISAAC and the International Union Against 
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Tuberculosis and Lung Disease (The Union). Its goals are to improve asthma care globally, 
with a focus on low- and middle-income countries (23), through enhanced surveillance, 
research collaboration, capacity building and access to quality-assured essential medicines. 
Given the large number of centres and countries involved with GAN, it was well placed to 
undertake such a survey. 
Based on the low number of national asthma strategies reported in the literature, our 
hypothesis was that most countries in the world do not have a national asthma strategy. 
GAN has collaborators in more than half of the world’s countries, which enabled a simple 
survey to be undertaken to answer a question about whether a country had a national 
asthma strategy for children and adults.  
 
Methods 
A cross-sectional survey of GAN centres was carried out between 29 April 2013 and 2 May 
2015. A GAN centre was one where an Expression of Interest form had been submitted to 
the GAN Global Centre (Auckland). The survey was by email survey and was sent to each 
centre’s principal investigator by the GAN Research Manager (PE). The survey was sent to 
GAN principal investigators in 276 centres in 120 countries, 41 were HICs and 79 LMICs, 
defined by the criteria used by the World Bank 2015 (24). 
The survey form had eight questions, one of which was “Has a national asthma strategy 
been developed in your country for the next five years? For children? (Yes/No/Don’t Know), 
for adults?” (Yes/No/Don’t Know). The remaining seven questions were about national 
asthma management guidelines in their country (not included in these analyses). 
Where conflicting answers were given by two or more investigators from different centres 
within a country, the GAN Global Centre staff entered into a discussion via email with the 
centre investigators until agreement between them was reached. 
Country findings were compared with the prevalence of asthma symptoms in 13-14 year olds 
in countries where this had been estimated in ISAAC Phase Three (25). Countries were 
categorised as high prevalence if the prevalence of current wheeze was >20%, and low 
prevalence if the prevalence of current wheeze was <10%. The relationship of national 
asthma strategies to changes in country prevalence of asthma symptoms in 13-14 year olds 
in countries where this had been estimated in ISAAC Phase Three (6) was also examined. 
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The data were entered into an excel spreadsheet and checked for apparent inconsistencies 
which were reconciled if appropriate. Simple descriptive analyses were undertaken. The Chi-
Squared test was used to compare responses about strategies between LMICs and HICs, 
and high and low prevalence countries with those answering ‘Yes’ compared with those ‘not 
answering Yes’ (‘No’ or ‘Don’t know’)(26). 
Role of the funding source 
The funders had no role in study design; in the collection, analyses, and interpretation of 
data; in the writing of the report; and in the decision to submit the paper for publication. 
 
Findings 
Of the 276 centre principal investigators in 120 countries, 213 (77.2%) investigators in 112 
(93.3%) countries completed the national asthma strategy questions. There were no 
responses from eight countries who were approached: three HICs and five LMICs. 
Conflicting answers were obtained from two or more centres in 16 countries, and agreement 
was subsequently reached. Of the 112 countries, 38 (33.9%) were HICs including 42.7% of 
the world’s 89 HICs; 74 (66.1%) were LMICs (Table) including 51.7% of the world’s 143 
LMICs.  
Of those 112 countries where the national asthma strategy questions were answered for 
children, 12 reported ‘Don’t Know’, 6 in HICs and 6 in LMICs. For adults, 16 reported ‘Don’t 
Know’, 8 in HICs and 8 in LMICs. 
Of the 112 countries, 26 (23.2%) reported a national asthma strategy for children, 24 
(21.4%) reported a national asthma strategy for adults, and 22 (19.6%) countries had 
strategies for both children and adults, and 28 (25%) had a national asthma strategy for at 
least one age group. These are illustrated in the Figure. 
Of the 28 countries who reported a national asthma strategy for at least one age group 13 
(46.4%) were HICs and 15 (53.6%) LMICs. Strategies were reported in 13/38 (34.2%) HICs 
and 15/74 (20.3%) LMICs; these differences between LMICs and HICs were not statistically 
significant p=0.107. 
In 81/112 (72%) countries the prevalence of asthma symptoms had been estimated in 
ISAAC.  Any national asthma strategy was significantly more common in countries with high 
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prevalence of current wheeze (>20%) than low prevalence (<10%): 11/13 (85%) and  7/31 
(22.6%) respectively,  p<0.001, with the remaining 37 countries having prevalence 10-20%. 
Of the 49 countries in whom time-trends in the prevalence of asthma symptoms had been 
estimated in ISAAC, any national asthma strategy was equally common in those whose 
prevalence rose (11/30) and in those in whom it fell (6/19) p=0.72 . 
Discussion 
In this survey of about half the worlds’ countries GAN was able to confirm our hypothesis 
that most countries in the world do not have a national asthma strategy. Only about one in 
four countries reported that they had a national asthma strategy. Of concern was that the 
proportion of LMICs with strategies was lower than HICs.  
About three in four countries surveyed had the prevalence of asthma symptoms measured in 
ISAAC, and of these, national asthma strategies were significantly more common in those 
with high prevalence compared with low prevalence. While on the face of it this seems 
logical – more asthma, more concern to lessen it, there are three caveats. Firstly, many of 
the countries with low prevalence of asthma symptoms and no national asthma strategy 
have very large populations, such as Indonesia, Brazil, Mexico, China, Philippines all in the 
top 12  most populous countries in the world in 2015, each with >100 million people (27).  
Small improvements in the management and outcomes for people with asthma in each of 
these countries would have a relatively big impact on the global burden of asthma. Secondly, 
in this survey one in four countries had not measured their asthma prevalence, which 
illustrates their lack of interest in asthma or difficulties engaging in world-wide 
epidemiological studies. Thirdly, the ISAAC data is already 13 years old (2002-3) and thus 
not coincident with survey, so the interpretation need caution. 
In the review of national and regional asthma strategies in Europe (11), a systematic search 
of the English literature in 2014 found only eight published national and regional asthma 
strategies in European Union countries: Finland (9), France (28), Ireland (29), Italy (30), The 
Netherlands (31), Lodz area of Poland (32), whole of Poland (33) and Portugal (13), with 
only three strategies having been evaluated (Finland, Poland, Portugal). Outside the 






There are likely to be many reasons for the low level of publication of national asthma 
strategies where they exist, including poor preparation with insufficient documentation, 
dissemination, implementation or evaluation, lack of appropriate training of primary health 
care professionals in diagnosis and treatment, poor access to quality–assured, essential 
asthma medicines, poor outcomes, unable to prepare an article for publication in English, 
and publication bias.  The absence of a national asthma strategy may reflect lack of 
recognition of asthma as a serious health problem including a lack of asthma prevalence , 
severity and mortality data, lack of government prioritisation of asthma among other non-
communicable diseases, lack of national health coordination, or lack of government 
commitment to improving national health issues.  
Not all national asthma strategies have been successful. Components of a successful 
asthma strategy were identified by Selroos and others : “An asthma programme should start 
with the universal commitments of stakeholders at all levels and the programme has to be 
endorsed by political and governmental bodies. When the national problems have been 
identified, the goals of the programme have to be clearly defined with measures to evaluate 
progress. An action plan has to be developed, including defined re-allocation of patients and 
existing resources, if necessary, between primary care and specialised healthcare units or 
hospital centres. Patients should be involved in guided self-management education and 
structured follow-up in relation to disease severity.” (11). However the same authors 
suggested that good results can also be achieved without formal national asthma 
programmes, as long as evidence-based guidelines are implemented and widely used (11). 
This is happening, for example, in Sweden, where recommendations (in Swedish) for 
diagnosis and treatment have been issued and updated by the National Board of Health and 
Welfare (34) and the Swedish Asthma and Allergy Foundation has recently issued a 
comprehensive national strategy document. Global asthma mortality reduced from 380,200 
in 1990 to 345,700 in 2010 (1). In Europe asthma mortality decreased from 6441 to 1164 
cases (82%) from 1990-2012 (35).  
In an earlier review of asthma projects and strategies in Argentina, Australia, Brazil, China, 
Japan, Mexico, the Philippines, Russia, South Africa, and Turkey discussed in 2009 by a 
group of experts in asthma care, the Advancing Asthma Care Network (36), all successful 
asthma strategies seemed to have the following characteristics: 1) improving early diagnosis 
and the introduction of first-line treatment with anti-inflammatory medication (mainly inhaled 
corticosteroids), 2) improving long-term disease control, 3) introducing simple means for 
guided self-management to proactively prevent exacerbations/attacks, and effective 
education and networking with general practitioners, nurses and pharmacists. A systematic 
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approach was recommended aiming to motivate and organise, and improvements can be 
achieved with relatively simple means. When multidisciplinary actions are being planned, all 
the main stakeholders should be represented.  
A more limited approach to improving asthma outcomes has been used successfully in pilot 
projects in LMICs, using standard case management, a term which “encompasses diagnosis 
of asthma, standardisation of treatment according to severity based on asthma guidelines, 
and patient education, coupled with a simple system for monitoring patient outcomes. 
Appropriate training of health care workers and availability of essential asthma medicines 
are key to the effectiveness of standard case management.” (37). Pilot studies in 2007-8 of 
the feasibility and effects of standard case management were applied in Benin (38), Haiyuan 
County, Anhui Province, China (39), Sudan (40) reduced hospitalisations in those 
completing the study. In El Salvador 2005-2010 (41), by using Practical Approach to Lung 
Health and essential asthma medicines free of charge, the number of patients being referred 
from primary to secondary or tertiary level dropped by 60%, with greater convenience for 
patients, and savings for health services. 
Political engagement, leadership and commitment are key components for developing 
effective national asthma strategies, and these are challenging and may not be easily 
achieved. The literature supports the view that programmes (strategies) are more likely to be 
successful where this has occurred; ‘lip service’ engagement on its own is of no value. The 
political organisation and health leadership in the country would undoubtedly influence the 
chance of success, as would co-ordinated access to affordable, quality-assured, essential 
asthma medicines. Identifying a political champion is a critical factor, and may be easier in 
some localities than others. In 2011 Global Initiative for Asthma launched a challenge to 
reduce hospitalisations, but so far the results have been modest (42). The motivation to 
tackle the asthma burden is not always self-evident, e.g. in places where private health-care 
dominates and hospitals compete. 
In this survey we asked only about national asthma strategies, not local or regional 
strategies. We know that there have been successful strategies in cities such as Salvador, 
Brazil (17), and these would have been missed in our survey. The survey asked about 
national asthma strategies for children separately from adults. Most who reported strategies 
had them for both age groups. The reasons why there would be separate strategies may 
include different approaches to the two populations, as often happens with national asthma 
management guidelines. Or there may have been ascertainment bias, with child–health 




This is a very large study, a high response rate of 93% was achieved, and data was reported 
from 112 countries, and the countries which responded were about half the world’s HICs and 
LMICs. The response rate was high because of the close relationship between the GAN 
Global Centre and GAN Principal Investigators.  
There may be different interpretations of the term “national asthma strategy”. National 
asthma guidelines alone should not be considered a National Asthma Strategy or 
Programme, although they are essential part of a Strategy. In this particular survey 
guidelines alone were unlikely to be confused with strategy, because national asthma 
management guidelines were asked about in the preceding seven questions in this email 
survey. However, the survey is likely to have missed asthma strategies which were not 
country-wide; these would be more likely in a very large country like Brazil or China. 
Additionally, some national asthma programmes may not have been understood to be 
strategies for the purpose of this survey.  
A successful programme is not expected to affect prevalence and incidence as we do not 
have effective interventions for these (23). However reduction in disease severity and 
improved control may be impressive. In Finland in early 1990s, 20% of patients were 
estimated to have uncontrolled (severe) asthma compared to 10% in 2001 and 4% in 2010 
(9, 43). A large reduction in the global burden of asthma and resultant costs could be 
achieved if more countries had asthma strategies as effective as Finland. The impressive 
results in Finland have not been replicated to the same extent in other countries to date. If 
the gains of the Finnish study were replicated by having effective national asthma strategies 
throughout the world, then the number of emergency visits would be estimated to fall by 24% 
in adults and 61% in children, hospital days would fall by about 54%, significant disability 
would decrease by about 76%, costs per patient per year would fall by 36%, and deaths by 
31%. Even if half these gains were achieved, there would be a large reduction of the burden 
and costs of asthma in the world. Such strategies are an appropriate way to address 
asthma, where the disability numbers and costs are disproportionately high, in contrast with 
the relatively high mortality found with other non-communicable diseases (23). 
We recommend that health authorities with governments in all countries should develop 
national asthma strategies with national action plans to improve detection of asthma and 
subsequently improve asthma management and reduce costs (7). Such a within-country 
public health approach will reach the greatest number of people with asthma in the country, 
to the greatest benefit.  
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The components of a successful national asthma strategy are government commitment, 
management by the health ministry, registry of outcome data before and after 
implementation (severity, asthma control, hospitalisations, mortality), continued education of 
health professionals, access to medical care and quality-assured, affordable, essential 
asthma medicines for everyone with asthma, follow-up programmes, asthma research.  
Such strategies should be evaluated, reported, and published. The problems to be 
addressed may be different in HICs compared to LMICs, and the solutions need to be 
tailored according to an individual country’s local needs, resources and organisation. 
Knowledge of asthma prevalence and severity and changes over time is fundamental to 
understanding the burden of asthma within each country and developing a strategy,  and this 
can be acheived using the methodology developed by ISAAC (44, 45) and continued 
(expanded to include adults) under GAN (46). The global burden of asthma potentially could 
be markedly reduced if more countries used effective national asthma strategies. 
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Albania No No LMIC 
Algeria No No LMIC 
Argentina No No LMIC 
Armenia No No LMIC 
Australia Yes Yes HIC 
Austria No No HIC 
Belarus No No LMIC 
Belgium Don’t Know Don’t Know HIC 
Benin No No LMIC 
Bolivia No No LMIC 
Bosnia and Herzegovina No Don’t Know LMIC 
Brazil No No LMIC 
Bulgaria No No LMIC 
Burkina Faso No No LMIC 
Cameroon No No LMIC 
Canada Yes Yes HIC 
Channel Islands No Don’t Know HIC 
Chile Don’t Know Don’t Know LMIC 
China Don’t Know No LMIC 
Colombia No No LMIC 
Congo Dem Rep No No LMIC 
Costa Rica Yes Yes LMIC 
Croatia Don’t Know Don’t Know HIC 
Cyprus No No HIC 
Denmark Don’t Know Don’t Know HIC 
Ecuador No No LMIC 
Egypt No No LMIC 
El Salvador Yes Yes LMIC 
Ethiopia Don’t Know Don’t Know LMIC 
Faroe Islands No No HIC 
Fiji No No LMIC 
Finland Yes Yes HIC 
France Yes Yes HIC 
French Polynesia No No HIC 
Gambia No No LMIC 
Georgia Yes Yes LMIC 
Germany No No HIC 
Ghana No No LMIC 
Greece No No HIC 
Grenada No No LMIC 
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Hong Kong Don’t Know Don’t Know HIC 
Hungary No No HIC 
India Yes No LMIC 
Indonesia No No LMIC 
Iran Yes Yes LMIC 
Ireland Yes Yes HIC 
Israel No No HIC 
Italy No No HIC 
Jamaica Don’t Know Don’t Know LMIC 
Japan Yes Yes HIC 
Jordan No No LMIC 
Kenya No No LMIC 
Korea, South Yes Yes HIC 
Kosovo No No LMIC 
Kuwait Yes Don’t Know HIC 
Latvia No No LMIC 
Libya No No LMIC 
Macedonia No No LMIC 
Malawi* Yes Yes LMIC 
Malaysia No No LMIC 
Mali No No LMIC 
Malta No No HIC 
Mexico No No LMIC 
Netherlands Don’t Know Don’t Know HIC 
New Caledonia No No HIC 
New Zealand No No HIC 
Nicaragua No No LMIC 
Nigeria No No LMIC 
Niue Don’t Know Don’t Know LMIC 
Norway No No HIC 
Oman No No HIC 
Pakistan No No LMIC 
Palau No No LMIC 
Palestine No No LMIC 
Panama Yes Yes LMIC 
Peru Yes Yes LMIC 
Philippines No No LMIC 
Poland Don’t Know Don’t Know HIC 
Portugal Yes Yes HIC 
Reunion Island No No HIC 
Romania No No LMIC 
Russia Yes No LMIC 
Samoa No No LMIC 
Saudi Arabia Yes Yes HIC 
Senegal No No LMIC 
Serbia Yes Yes LMIC 
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Sierra Leone No No LMIC 
Singapore No Don’t Know HIC 
South Africa No No LMIC 
Spain No No HIC 
Sri Lanka No No LMIC 
Sudan No Yes LMIC 
Syrian Arab Republic No No LMIC 
Taiwan Yes Don’t Know LMIC 
Thailand No No LMIC 
Togo Don’t Know No LMIC 
Tokelau No No LMIC 
Tonga No Don’t Know LMIC 
Trinidad and Tobago No No HIC 
Tunisia No No LMIC 
Turkey Yes Yes LMIC 
Tuvalu No No LMIC 
Uganda No No LMIC 
Ukraine No Yes LMIC 
United Arab Emirates Yes Yes HIC 
United Kingdom Yes Yes HIC 
United States Yes Yes HIC 
Uruguay No No LMIC 
Vanuatu No No LMIC 
Vietnam Yes Yes LMIC 
Zambia No No LMIC 
Zimbabwe No No LMIC 
 
* LMIC = Low or Medium Income Country (by World Bank assessment). 
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Legend for figure 
World map showing the countries with national asthma strategies (blue), the ones without 
(red), don’t know (yellow) did not respond (black), or were not in the survey (grey) . 
 
 
GAN Study Group 
GAN Steering Group: Neil Pearce Innes Asher, Nils Billo, Karen Bissell, Philippa Ellwood, 
Asma El Sony, Luis Garcia-Marcos, Chiang Chen-Yuan, Javier Mallol, Guy Marks, David 
Strachan and GAN Principal Investigators for this study: Albania: A Priftanji (Tiranë); 
Algeria: R Boukari (Blida), B Benhabylès (Wilaya of Algiers); Argentina: N Salmun (Buenos 
Aires), FA Castracane (Mendoza), M Gómez (Salta); Armenia: A Baghdasaryan (Yerevan); 
Australia: A Tai (Adelaide), S Burgess (Brisbane), J Mattes (Newcastle), G Marks (Sydney); 
Austria: J Riedler (Salzburg), G Haidinger (Urfahr-umgebung); Belarus: A Shpakou 
(Grodno); Belgium: J Weyler (Antwerp); Benin: M Gninafon (Cotonou); Bolivia: J Aguirre de 
Abruzzese (Santa Cruz); Bosnia and Herzegovina: S Domuz (Prijedor); Brasil: PA Camargos 
(Belo Horizonte), N Rosário (Curitiba), HV Brandão (Feira de Santana), AC Porto Neto 
(Passo Fundo), AM Menezes (Pelotas), GB Fischer (Porto Alegre), M de Britto (Recife), FC 
Kuschnir (Rio de Janeiro), NF Wandalsen (Santo André), D Solé (São Paulo South); 
Bulgaria: TB Mustakov (Sofia); Burkina Faso: E Birba (Bobo-Dioulasso); Cameroon: EW 
Pefura Yone (Bafoussam), BH Mbatchou Ngahane (Douala); Canada: T To (Ontario), DC 
Rennie (Saskatoon); Channel Islands: P Standring (Guernsey); Chile: MA Calvo Gil 
(Valdivia); China: Y-Z Chen (Beijing), X Kan (Hefei), Y Lin (Tayuan); Colombia: E Garcia 
(Bogota), J Niederbacher (Bucaramanga), GA Ordoñez (Cali); Costa Rica: ME Soto-Quirós 
(Costa Rica); Croatia: S Banac (Rijeka); Cyprus: P Yiallouros (Nicosia); Denmark: L Lochte 
(Copenhagen); Ecuador: P Cooper (Esmeraldas), S Barba (Quito); Egypt: A Mokhtar 
(Alexandria), M El Falaki (Cairo); El Salvador: M Figueroa Colorado (San Salvador); 
Ethiopia: A Berihu (Mekelle); Faroe Islands: P Weihe (Faroe Islands); Fiji: VA Lal (Suva); 
Finland: M Mäkelä (Helsinki); France: C Raherison (Bordeaux), I Annesi-Maesano (Créteil, 
West Marne), D Charpin (Marseille) ; Gambia: S Anderson (Fajara); Georgia: M Gotua 
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(Kutaisi, Tbilisi); Germany: E von Mutius (Munich); Ghana: NF Clement (Accra), EO Addo-
Yobo (Kumasi); Greece: C Gratziou (Athens), J Tsanakas (Thessaloniki); Grenada: M 
Akpinar-Elci (Grenada); Hong Kong: CK Lai (Hong Kong); Hungary: Z Novák (Szeged); 
India: BK Reddy (Bangalore), M Sabir (Bikaner), M Singh (Chandigarh), R Ilangho 
(Chennai), V Singh (Jaipur), A Maitra (Kolkata (10)), M Mukherjee (Kolkata (14)), TU 
Sukumaran (Kottayam), S Awasthi (Lucknow), UA Pai (Mumbai (7)), AV Pherwani (Mumbai 
(11)), SK Sharma (New Delhi), S Varkki (Vellore); Indonesia: CB Kartasasmita (Bandung); 
Iran: M Cheraghi (Ahvaz), M-R Masjedi (Birjand, Bushehr, Rasht, Tehran, Zanjan), M Karimi 
(Yazd); Ireland: P Manning (Ireland); Israel: T Shohat (Israel); Italy: S Bonini (Ascoli Piceno), 
MG Petronio (Empoli), S La Grutta (Palermo), F Forastiere (Roma), S Piffer (Trento); 
Jamaica: E Kahwa (Kingston); Japan: H Odajima (Fukuoka), S Yoshihara (Tochigi); Jordan: 
F Abu-Ekteish (Amman), O Al Omari (Jerash); Kenya: FO Esamai (Eldoret), EI Amukoye 
(Nairobi); Korea, South: S-J Hong (Seoul); Kosovo: L Neziri-Ahmetaj (Prishtina); Kuwait: JA 
al-Momen (Kuwait); Latvia: V Svabe (Riga); Libya: M Shenkada (Tripoli); Macedonia: E 
Vlaski (Skopje); Malawi: K Mortimer (Blantyre); Malaysia: J de Bruyne (Klang Valley); Mali: Y 
Toloba (Bamako); Malta: S Montefort (Malta); Mexico: R García-Almaráz (Ciudad Victoria), 
DD Hernández-Colín (Guadalajara), JV Mérida-Palacio (Mexicali), BE Del-Río-Navarro 
(Mexico City North), SN González-Díaz (Monterrey), CA Jiménez González (San Luis 
Potosí); Netherlands: B Brunekreef (Utrecht); New Zealand: I Asher (Auckland), C Moyes 
(Bay of Plenty), P Pattemore (Christchurch), S Currie (Hawkes Bay), R Hancox (Otago), D 
Graham (Waikato), J Douwes (Wellington); Nicaragua: MZ Cordero Rizo (Matagalpa); 
Nigeria: B Garba Ilah (Gusau), AG Falade (Ibadan), GE Erhabor (Ife), N Onyia (Lagos), AH 
Gabdo (Maiduguri); Niue: M Pulu (Niue Island); Norway: W Nystad (Oslo, Tromsø); 
Nouvelle-Calédonie: I Annesi-Maesano (Nouvelle-Calédonie); Oman: O Al-Rawas (Al-Khod); 
Pakistan: MO Yusuf (Islamabad); Palau: BM Watson (Republic of Palau); Palestine: N El 
Sharif (North Gaza, Ramallah); Panama: G Cukier (David-Panamá); Peru: P Chiarella 
(Lima), W Checkley (Puno, Tumbes); Philippines: R Pagcatipunan (Metro Manila); Poland: G 
Lis (Kraków); Polynésie française: I Annesi-Maesano (Polynésie française); Portugal: J 
Rosado Pinto (Lisboa); République démocratique du Congo: B Kabengele Obel (Kinshasa); 
Réunion Island: I Annesi-Maesano (Reunion Island); Romania: D Deleanu (Cluj-Napoca); 
Russia: EG Kondiourina (Novosibirsk), E Kamaltynova (Tomsk); Samoa: L Esera-Tulifau 
(Apia); Saudi Arabia: BR Al-Ghamdi (Abha), A Yousef (Alkhobar); Senegal: NO Toure 
(Dakar); Serbia: Z Zivkovic (Belgrade), D Višnjevac (Indjija), M Hadnadjev (Novi Sad); Sierra 
Leone: G Fadlu-Deen (Freetown); Singapore: DY Goh (Singapore); South Africa: HJ Zar 
(Cape Town), K Voyi (Ekurhuleni, Polokwane), ), R Masekela (Pretoria); Spain: I Carvajal-
Urueña (Asturias), RM Busquets (Barcelona), C González Díaz (Bilbao), A Rabadán-
Asensio (Cádiz), L García-Marcos (Cartagena), A Arnedo-Pena (Castellón), A López-
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Silvarrey Varela (La Coruña), C Luna (Madrid), J Wärnberg (Málaga), EG Pérez-Yarza (San 
sebastián), M Praena-Crespo (Sevilla), MM Morales Suárez-Varela (Valencia); Sri Lanka: 
KD Gunasekera (Colombo), ST Kudagammana (Peradeniya); Sudan: S Hassanain 
(Gadarif), A El Sony (Khartoum); Syrian Arab Republic: Y Mohammad (Lattakia); Taiwan: YL 
Guo (Tainan), J-L Huang (Taipei); Thailand: P Vichyanond (Bangkok), S Phumethum 
(Chantaburi), M Trakultivakorn (Chiang Mai), J Teeratakulpisarn (Khon Kaen); Togo: O 
Tidjani (Lome); Tokelau: T Iosefa (Tokelau); Tonga: G Aho (Nuku'alofa); Trinidad and 
Tobago: D Dookeeram (Trinidad and Tobago); Tunisia: A Hamzaoui (Ariana); Turkey: A 
Yorgancioglu (Ankara); Tuvalu: N Ituaso-Conway (Funafuti); Uganda: W Worodria 
(Kampala); Ukraine: O Fedortsiv (Ternopil); United Arab Emirates: B Mahboub (Sharjah); 
United Kingdom: AH Mansur (Birmingham); United States: RP Doshi (Fort Wayne), K Yeatts 
(North Carolina), GJ Redding (Seattle), M Akpinar-Elci (Virginia); Uruguay: M Valentin-
Rostan (Montevideo); Vanuatu: G Harrison (Port Vila); Vietnam: LT Le (Ho Chi Minh); 
Zambia: S Wa Somwe (Lusaka); Zimbabwe: P Manangazira (Zimbabwe) 
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